Mark Kong CFA

Stock Analyst at DBS

(2.74)
# 2,692
Out of 4,339 analysts
23
Total ratings
25%
Success rate
7.1%
Average return

Stocks Rated by Mark Kong CFA

Sino Biopharmaceutical Limited
May 20, 2026
Initiated Coverage: Buy
Price Target: $6.5
Current: $5.22
Upside: +24.52%
BeOne Medicines AG
May 7, 2026
Maintained: Buy
Price Target: $290
Current: $184.50
Upside: +57.18%
Consun Pharmaceutical Group Limited
Mar 27, 2026
Maintained: Buy
Price Target: $22$26
Current: $14.44
Upside: +80.06%
Laekna, Inc.
Mar 20, 2026
Maintained: Buy
Price Target: $24
Current: $13.17
Upside: +83.45%
Sinopharm Group Co. Ltd.
Dec 12, 2024
Upgraded: Buy
Price Target: $25
Current: $17.55
Upside: n/a
China Resources Medical Holdings Company Limited
Oct 24, 2024
Maintained: Buy
Price Target: $7.5
Current: $2.52
Upside: n/a
Sanofi
Oct 11, 2024
Maintained: Buy
Price Target: n/a
Current: $44.29
Upside: n/a
Vertex Pharmaceuticals
Oct 8, 2024
Maintained: Hold
Price Target: n/a
Current: $434.52
Upside: n/a
AbbVie
Sep 13, 2024
Maintained: Hold
Price Target: n/a
Current: $215.70
Upside: n/a
Moderna
Sep 13, 2024
Maintained: Buy
Price Target: n/a
Current: $46.88
Upside: n/a